Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating Pumitamig alone or in combination with ipilimumab or cabozantinib in adults with advanced renal cell carcinoma, current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Pumitamig
• cabozantinib (cabozantinib)
• ipilimumab (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Advanced Renal Cell Carcinoma (RCC) | Phase 1, Phase 2 | Status: RECRUITING